MedTrace Logo

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

NCT00064376 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-01-29

No results posted yet for this study

Summary

RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.

PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.

Conditions

Interventions

DRUG

paricalcitol

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • H. Phillip Koeffler, MD · Cedars-Sinai Medical Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
25 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2005-11-30
Completion
2005-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064376 on ClinicalTrials.gov